Product Information
ACYCLOVIR 200 MG/5 ML SUSP is a generic product labeled by Advagen Pharma Ltd., priced at $0.0764 per ML under NDC 72888007917. Its NADAC has been published 78 times since Apr 9, 2025.
FDA first approved this application on Aug 18, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/5mL
Manufacturer
Advagen Pharma Ltd.NDC
72888007917
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACYCLOVIRApproval Type
Generic (ANDA)
FDA Application
ANDA215724FDA Approved
8/18/2022
TE Code
AB
On Market Since
1/9/2021
Pharmacological Classes
Price Statistics
The NADAC for ACYCLOVIR 200 MG/5 ML SUSP has been published 78 times since Apr 9, 2025, and over the history we have for it it has declined 12.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0764 per ML |
|---|---|
| All-time high | $0.0973 (Aug 13, 2025) |
| All-time low | $0.0640 (Jul 22, 2026) |
| 52-week high | $0.0869 |
| 52-week low | $0.0640 |
| Median price | $0.0807 |
| Average price | $0.0808 |
| Largest weekly change | +10.2% (Sep 23, 2026) |
| Weeks tracked | 78 |
| Tracking since | Apr 9, 2025 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Advagen Pharma Ltd. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acyclovir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACYCLOVIR 200 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for ACYCLOVIR 200 MG/5 ML SUSP, manufactured by Advagen Pharma Ltd., is $0.0764 per ML (NDC 72888007917), effective Sep 30, 2026.
How has the price of ACYCLOVIR 200 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for ACYCLOVIR 200 MG/5 ML SUSP has declined 12.7%. It has been tracked across 78 weekly CMS publications since Apr 9, 2025.
What are the highest and lowest recorded NADAC prices for ACYCLOVIR 200 MG/5 ML SUSP?
Since Apr 9, 2025, the NADAC for ACYCLOVIR 200 MG/5 ML SUSP has ranged from a low of $0.0640 (Jul 22, 2026) to a high of $0.0973 (Aug 13, 2025), with a median of $0.0807 per ML.
Are there cheaper alternatives to ACYCLOVIR 200 MG/5 ML SUSP?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ACYCLOVIR 200 MG/5 ML SUSP in a comparable dosage form, but none are currently priced below it.
Who manufactures ACYCLOVIR 200 MG/5 ML SUSP?
ACYCLOVIR 200 MG/5 ML SUSP (NDC 72888007917) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.